Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis
- 7 August 2015
- journal article
- Published by Elsevier in Tuberculosis
- Vol. 95 (6) , 786-794
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Design and development of novel Mycobacterium tuberculosis l-alanine dehydrogenase inhibitorsEuropean Journal of Medicinal Chemistry, 2015
- Development of 5-nitrothiazole derivatives: Identification of leads against both replicative and latent Mycobacterium tuberculosisBioorganic & Medicinal Chemistry Letters, 2012
- Latent tuberculosis: what the host “sees”?Immunologic Research, 2011
- Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinolineJournal of Antimicrobial Chemotherapy, 2010
- Proteasome target to tackle non-replicating TBNature Reviews Drug Discovery, 2009
- Overexpression, purification and crystallization of lysine ∊-aminotransferase (Rv3290c) fromMycobacterium tuberculosisH37RvActa Crystallographica Section F Structural Biology and Crystallization Communications, 2006
- Capreomycin is active against non-replicating M. tuberculosisAnnals of Clinical Microbiology and Antimicrobials, 2005
- Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profilingMolecular Microbiology, 2002
- Use of MTT colorimetric assay to measure cell activationJournal of Immunological Methods, 1986
- L-lysine-.alpha.-ketoglutarate aminotransferase. II. Purification, crystallization, and propertiesBiochemistry, 1968